Refining the serum miR-371a-3p test for viable germ cell tumor detection: identification and definition of an indeterminate range.
Journal
Research square
Titre abrégé: Res Sq
Pays: United States
ID NLM: 101768035
Informations de publication
Date de publication:
21 Mar 2023
21 Mar 2023
Historique:
medline:
31
3
2023
entrez:
30
3
2023
pubmed:
31
3
2023
Statut:
epublish
Résumé
Circulating miR-371a-3p has excellent performance in the detection of viable (non-teratoma) GCT pre-orchiectomy; however, its ability to detect occult disease is understudied. To refine the serum miR-371a-3p assay in the minimal residual disease setting we compared performance of raw (Cq) and normalized (∆Cq, RQ) values from prior assays, and validated interlaboratory concordance by aliquot swapping. Revised assay performance was determined in a cohort of 32 patients suspected of occult retroperitoneal disease. Assay superiority was determined by comparing resulting receiver-operator characteristic (ROC) curves using the Delong method. Pairwise t-tests were used to test for interlaboratory concordance. Performance was comparable when thresholding based on raw Cq
Identifiants
pubmed: 36993198
doi: 10.21203/rs.3.rs-2644890/v1
pmc: PMC10055551
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : P30 CA142543
Pays : United States
Organisme : NCI NIH HHS
ID : UH3 CA240688
Pays : United States
Commentaires et corrections
Type : UpdateIn
Références
J Clin Oncol. 2019 Nov 20;37(33):3090-3098
pubmed: 31553692
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
Sci Rep. 2021 Aug 2;11(1):15582
pubmed: 34341387
Br J Cancer. 2016 Jan 19;114(2):151-62
pubmed: 26671749
Urology. 2007 Mar;69(3):557-9
pubmed: 17382165
Mol Diagn Ther. 2021 May;25(3):273-281
pubmed: 33886084
BMC Bioinformatics. 2011 Mar 17;12:77
pubmed: 21414208
Ann Oncol. 2017 Apr 1;28(4):899-902
pubmed: 28137740
Front Oncol. 2022 Dec 08;12:1056823
pubmed: 36568207
Eur Urol Focus. 2021 Sep;7(5):1137-1142
pubmed: 33121935
J Urol. 2021 Jan;205(1):137-144
pubmed: 32856980
J Clin Oncol. 2015 Jan 1;33(1):51-7
pubmed: 25135991
J Clin Oncol. 2010 Feb 1;28(4):531-6
pubmed: 20026808
Eur Urol. 2020 Feb;77(2):290-292
pubmed: 31699528
J Mol Diagn. 2022 Aug;24(8):867-877
pubmed: 35934321
J Urol. 2021 Jun;205(6):1569-1576
pubmed: 33617328